Abstract
Abstract Breast cancer is the most prevalent form of cancer among women in the United States. Treatment is greatly complicated by metastasis of cells from the primary tumor site, which increases mortality; about 40 percent of breast cancer patients will relapse and develop metastatic disease. Eighty percent of breast cancer patients are treated with adjuvant chemotherapy to decrease their risk of getting metastasis, while as indicated previously only 40% of them will eventually relapse and develop metastatic disease. Despite this precautionary measure, adjuvant chemotherapy is shown to increase 15-years survival of such patients by only 3-10%. Further, about 40,000 women die of breast cancer every year due to undetected early metastasis. Clearly detection of metastatic disease has major clinical implications. Identifying specific blood serum biomarkers that accurately and reproducibly indicate the presence of metastatic disease could greatly improve treatment, as they could substitute for more invasive procedures that are in current use and be used to monitor remission at higher resolution. Analysis of protein content in serum has been widely used as a method for biomarker identification, but detection, identification, and analysis of short peptide biomarkers faces technical challenges that have prevented widespread application of this approach. We report here results from a proteomics study aimed at identifying and characterizing short peptide biomarkers in serum samples taken from patients with stage I and stage III breast cancer. Serum samples contain over 2500 distinct peaks representing distinct peptides. A preliminary analysis reveals that the abundance of 92 peptides are significantly reduced in samples from patients with stage III disease, while the abundance of 64 peptides show significant increase in stage III sera. A large number of additional peptides show smaller changes in abundance in sera from the two patient groups. Our future work will be to characterize the identity of the serum biomarkers identified and validate their appearance or disappearance in a large cohort of patients. Citation Format: Adhari Abdullah Al Za'abi, Steven Graves, Marc Hansen. Identification and characterization of serum biomarkers associated with metastatic progression of breast cancer. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr C24.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
